Today: 8 June 2026
Goldman Sachs stock: GS steadies at $905 as top lawyer exit clouds holiday-shortened week
15 February 2026
2 mins read

Goldman Sachs stock: GS steadies at $905 as top lawyer exit clouds holiday-shortened week

New York, Feb 15, 2026, 13:55 EST — The market has closed.

  • Goldman Sachs shares barely budged in the previous session, following news that the bank’s chief legal officer plans to step down on June 30.
  • With U.S. markets shut Monday for Presidents Day, banks and brokers are heading into a shortened trading week.
  • Traders eye the Epstein document releases for possible ripple effects, while also tuning in to the Fed’s next policy cues.

Goldman Sachs stock finished Friday just barely higher, inching up under 0.1% to close at $905.14. Shares moved between $869.80 and $908.35 during the session, with news circulating that chief legal officer Kathryn Ruemmler is set to retire June 30.

This shakeup hits at a sensitive moment: the chief legal officer runs point on a big bank’s compliance and reputation shields, and now there’s renewed heat over Jeffrey Epstein. According to Reuters, Justice Department records just made public reveal Ruemmler took gifts from Epstein and counseled him on how to deal with press questions about his crimes.

The timing bumps up against a long weekend. Per the exchange’s holiday calendar, the New York Stock Exchange will shut on Monday, Feb. 16 for Washington’s Birthday.

David Solomon, the chief executive, told CNBC he “reluctantly accepted” Ruemmler’s resignation, adding that she described the ongoing coverage as “noise and distraction” for the firm. According to Solomon, the situation made her job tougher, and she ultimately decided it was the right moment to leave. Reuters

The Associated Press says Ruemmler plans to step down at the end of June, following a Justice Department release of emails that highlighted her ties to Epstein—along with gifts she accepted from him. Those revelations have thrown a spotlight on potential issues with Goldman’s conflict and gift rules.

Trading in Goldman shares got volatile fast. Early Friday, the stock tumbled and pulled the Dow lower, with Goldman one of the hardest hit, according to MarketWatch. Later, shares managed to pare back much of those losses.

Investors paused after softer U.S. inflation numbers, yet the market tape dragged heading into the holiday, with all three major indexes chalking up their heftiest weekly drops since November, Reuters reported. “We’ve been on wobbly legs a couple of weeks now and with the three-day weekend approaching, it’s not surprising,” said Michael James of Rosenblatt Securities. Reuters

Goldman’s news lands as deal-making remains turbulent. A number of firms have scaled back or pushed out their U.S. IPO timelines for 2026, wary of volatile markets pressuring valuations. Yet, Goldman analysts—cited by Reuters—still point to more listings on tap this year, even as the recent software sector selloff spotlights risks around pricing.

The risk on the other side isn’t complicated: reputation issues don’t tend to resolve neatly or quickly. Should the Justice Department’s Epstein files reveal additional information, the bank might find itself under fresh scrutiny from clients and counterparties—regardless of whether anyone can immediately gauge the financial toll.

Next up for investors: they’ll get their first real look at market sentiment when U.S. trading resumes Tuesday. Eyes then jump to the Federal Reserve’s Jan. 27–28 meeting minutes, slated for release at 2 p.m. Wednesday, Feb. 18. Those minutes could easily sway rate bets and send bank stocks moving.

Stock Market Today

  • Indian Stock Market July 8: Cautious Start Amid Middle East Tensions
    June 8, 2026, 9:21 AM EDT. Indian stocks are poised for a cautious open on June 8, impacted by rising Middle East tensions and a global market selloff. The GIFT Nifty index fell over 1%, as Asian markets including South Korea and Japan declined sharply, signaling increased investor risk aversion. Higher crude oil prices and a rebound in gold indicate a shift towards defensive assets. Investors will watch key domestic developments in companies like TVS Motor, RailTel, KNR Constructions, Creative Newtech, Amber Enterprises, and Ixigo. Fundraising activities at Zee, ASM Technologies, and Gujarat Themis, along with regulatory issues at Yes Bank, 5Paisa, and Reliance Infrastructure, will also remain in focus.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next
Previous Story

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop